Amniotic Products Market Report 2025

The amniotic products market size has grown strongly in recent years. It will grow from $0.99 billion in 2024 to $1.08 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to rising prevalence of burn injuries, increasing demand for regenerative medicine, growing adoption of amniotic products in surgical wounds, rising awareness of amniotic products as a viable treatment avenue, global expansion of amniotic products.

The amniotic products market size is expected to see strong growth in the next few years. It will grow to $1.52 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing patient preference for non-invasive therapies, rising prevalence of chronic wounds, collaborations and partnerships, impact of COVID-19, rising prevalence of ophthalmic disorders, increasing healthcare expenditure. Major trends in the forecast period include continuous evolution of product technology, strong growth potential, regional dynamics, impact of COVID-19 and a looming global recession, growth in the target patient population, emerging economies.

The rising incidence of trauma and accident cases is expected to drive the growth of the amniotic products market in the coming years. Trauma refers to sudden physical injuries that require immediate medical attention, while accidents include various unintentional incidents, such as slips, falls, vehicle collisions, or sports injuries. Third-degree burn injuries, for instance, are treated using full-thickness skin excision and hyper-dry human amniotic membrane wound dressings. For example, in April 2024, Eurostat, a Luxembourg-based statistical office of the European Union, reported that road traffic accidents in the EU led to 20,653 fatalities in 2022, a 4% increase compared to the 19,917 deaths in 2021. Thus, the rising number of trauma and accident cases is fueling the growth of the amniotic products market.

The growing demand for surgical procedures is expected to further propel the growth of the amniotic products market. Surgical procedures involve medical interventions performed by qualified surgeons to treat, repair, remove, or replace parts of the body affected by disease or injury. Amniotic products are advantageous in surgical procedures as they promote tissue regeneration and healing, minimize inflammation at surgical sites, contribute to faster recovery, reduce postoperative pain, and improve tissue repair and protection. For instance, in June 2024, the American Society of Plastic Surgeons (ASPS), a US-based plastic surgery organization, reported that liposuction was the most popular plastic surgery in 2023, with nearly 350,000 procedures performed, marking a 7% increase from 2022. Additionally, hand surgeries totaled 207,887, a 2% increase, while maxillofacial surgeries reached 52,868, up 1% compared to the previous year. Consequently, the rising demand for surgical procedures is driving the growth of the amniotic products market.

Innovation stands as a central trend propelling advancements in the amniotic products market. Key industry players are focusing on developing pioneering products to fortify their standing within this competitive landscape. For example, Versea Health Inc., a US-based life science company, introduced Biovance 3L ocular tri-layer human amniotic membrane in November 2022. This product, available in sheet and disc forms, specifically targets surgical and ocular segments. Biovance 3L and Biovance 3L Ocular are tri-layer human amniotic membrane products designed to offer an extracellular matrix for biological membrane covering, fostering healing and tissue growth during wound recovery.

Major companies in the amniotic products market are directing their efforts towards innovative solutions such as dual-layer allografts to drive market growth and bolster revenues. Dual-layer allografts serve patients with complex surgical wounds, burns, and non-healing acute or chronic wounds. For instance, in February 2022, Amnio Technology LLC, a US-based company specializing in amnion-derived technologies, unveiled the palingen dual-layer membrane and dual-layer palingen X-membrane. These advanced allografts target challenging surgical wounds and leverage a dual-layered structure. The design utilizes two Advantek processes, ensuring unidirectional application while preserving the crucial regulatory proteins and extracellular matrix constituents inherent in amniotic tissue. The dual-layer construction and specialized Advantek processes in palingen membranes safeguard the regulatory proteins and extracellular matrix constituents, enhancing their effectiveness in addressing challenging wounds and facilitating tissue repair and regeneration.

In July 2022, Sanara MedTech Inc., a US-based medical technology firm, acquired Scendia Biologics, LLC, for $0.0074 billion. This acquisition is intended to expand Sanara's product portfolio in surgical and chronic wound care by incorporating a substantial range of advanced biologic products, which will ultimately enhance patient outcomes and lower overall costs. Scendia Biologics, LLC, a US-based provider, specializes in high-quality regenerative and fusion technologies, including amniotic products.

Major companies operating in the amniotic products market include Stryker Corporation, Smith & Nephew plc, Integra LifeSciences Holdings Corporation, Lucina BioSciences LLC, Bioventus LLC, Organogenesis Inc., MiMedx Group, AlloSource, Orthofix US LLC, ACell Inc., Aziyo Biologics Inc., TissueTech Inc., Amino Technology LLC, LifeCell International Pvt. Ltd., Tissue Regenix Group plc, Aroa Biosurgery Limited, Skye Biologics Inc., Celularity Inc., NuVision Biotherapies Ltd., VIVEX Biologics Inc., Genesis Biologics Inc., Applied Biologics LLC, Next Biosciences, Surgenex LLC.

North America was the largest region in the amniotic products market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amniotic products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the amniotic products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Amniotic products encompass ortho-biologic solutions that leverage materials derived from amniotic sources, including amniotic membranes and fluid products, to promote healing and reduce inflammation in joints. The application of amniotic products at the site of injury facilitates tissue growth, contributing to the overall recovery process.

The primary categories of amniotic products include amniotic membranes and amniotic suspensions. Amniotic membranes consist of the innermost layer of the placenta, featuring a robust foundation membrane and an avascular stromal matrix. These membranes find applications in surgical dressing for burns, tissue restoration in oral and bladder procedures, as well as interventions such as tympanoplasty, arthroplasty, omphalocele repair, and prevention of adhesions in pelvic and abdominal surgeries. Amniotic products are utilized across medical specialties, including wound care, orthopedics, ophthalmology, and others, with their deployment occurring in hospitals, ambulatory surgical centers, and similar healthcare settings.

The amniotic products market research report is one of a series of new reports that provides amniotic products market statistics, including amniotic products industry global market size, regional shares, competitors with an amniotic products market share, detailed amniotic products market segments, market trends and opportunities, and any further data you may need to thrive in the amniotic products industry. This amniotic products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The amniotic products market consists of sales of amniotic tissue matrix and amniotic fluid cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.